Immunogenicity and safety of a primary series of a new fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (Hexaxim(TM)) co-administered with Prevenar(TM) and Rotarix(TM) in healthy children in Latin America

摘要

Background: Lot-to-lot consistency study assessing primary series vaccination with a new, fully liquid, DTaP–IPV–Hep B–PRP-T vaccine (Hexaxim? - an AcXim family vaccine), incorporating the new Hansenula polymorpha–derived Hep B antigen (Sanofi Pasteur), co-administered with Prevenar? and Rotarix?.